Evidence map›Paper›PMID 26313548›Full record

ArticlePLoS pathogens2015

Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.

Glynis Dunn, Dimitra Klapsa, Thomas Wilton, Lindsay Stone, Philip D Minor, Javier Martin

Abstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed.

  1. Characterization of Household and Community Shedding and Transmission of Oral Polio Vaccine in Mexican Communities With Varying Vaccination Coverage.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Trial
  2. Trial
  3. Article
  4. Environmental surveillance of pathogens in Africa.Applied and environmental microbiology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Glynis DunnDivision of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.
Dimitra KlapsaDivision of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.
Thomas WiltonDivision of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.
Lindsay StoneDivision of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.
Philip D MinorDivision of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.
Javier MartinDivision of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.

Funding

Department of Health
6 · The paper itself

Abstract

There are currently huge efforts by the World Health Organization and partners to complete global polio eradication. With the significant decline in poliomyelitis cases due to wild poliovirus in recent years, rare cases related to the use of live-attenuated oral polio vaccine assume greater importance. Poliovirus strains in the oral vaccine are known to quickly revert to neurovirulent phenotype following replication in humans after immunisation. These strains can transmit from person to person leading to poliomyelitis outbreaks and can replicate for long periods of time in immunodeficient individuals leading to paralysis or chronic infection, with currently no effective treatment to stop excretion from these patients. Here, we describe an individual who has been excreting type 2 vaccine-derived poliovirus for twenty eight years as estimated by the molecular clock established with VP1 capsid gene nucleotide sequences of serial isolates. This represents by far the longest period of excretion described from such a patient who is the only identified individual known to be excreting highly evolved vaccine-derived poliovirus at present. Using a range of in vivo and in vitro assays we show that the viruses are very virulent, antigenically drifted and excreted at high titre suggesting that such chronic excreters pose an obvious risk to the eradication programme. Our results in virus neutralization assays with human sera and immunisation-challenge experiments using transgenic mice expressing the human poliovirus receptor indicate that while maintaining high immunisation coverage will likely confer protection against paralytic disease caused by these viruses, significant changes in immunisation strategies might be required to effectively stop their occurrence and potential widespread transmission. Eventually, new stable live-attenuated polio vaccines with no risk of reversion might be required to respond to any poliovirus isolation in the post-eradication era.

Indexed as

Virus ReplicationAdultAnimalsBase SequenceHumansImmunizationImmunologic Deficiency SyndromesMaleMiceMice, TransgenicMolecular Sequence DataPoliomyelitisPoliovirusPoliovirus VaccinesPoliovirus Vaccines

Identifiers

PMID26313548
PMCPMC4552295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.